Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) EBIT per Share : $-5.69 (TTM As of Dec. 2020)

View and export this data going back to 2005. Start your Free Trial

What is Sunesis Pharmaceuticals EBIT per Share?

Sunesis Pharmaceuticals's EBIT per Share for the three months ended in Dec. 2020 was $-0.93. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2020 was $-5.69.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Sunesis Pharmaceuticals's EBIT per Share or its related term are showing as below:

SNSS's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.45
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Sunesis Pharmaceuticals's EBIT for the three months ended in Dec. 2020 was $-4.81 Mil.

Sunesis Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Sunesis Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals EBIT per Share Chart

Sunesis Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

EBIT per Share

Get a 7-Day Free Trial

-81.03

-48.66

-25.04

-9.17

-5.29

Sunesis Pharmaceuticals Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
EBIT per Share	Get a 7-Day Free Trial															-1.64	-1.79	-1.99	-0.98	-0.93

Sunesis Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Sunesis Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2020 is calculated as

	EBIT per Share		(A: Dec. 2020 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-21.308	/	4.027
=	-5.29

Sunesis Pharmaceuticals's EBIT per Share for the quarter that ended in Dec. 2020 is calculated as

	EBIT per Share		(Q: Dec. 2020 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.807	/	5.179
=	-0.93

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.69

Sunesis Pharmaceuticals (NAS:SNSS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Sunesis Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (NAS:SNSS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

http://www.sunesis.com

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Executives

Steve Carchedi	director	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Nicole Onetto	director	58 S SERVICE RD, MELVILLE NY 11747
Henry Ward Wolff	director	6701 KAISER DRIVE, FREMONT CA 94555
Steven B Ketchum	director	2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
James W Young	director
Homer L Pearce	director	84 CLIFDEN, ZIONSVILLE IN 46077
Dayton Misfeldt	director, officer: See Remarks	C/O BAY CITY CAPITAL LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
David C Stump	director
Tina Gullotta	officer: VP, Finance	SUNESIS PHARMACEUTICALS,INC, 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William P. Quinn	officer: See Remarks	SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Judith A. Fox	officer: See Remarks	SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Aisling Capital Iv, Lp	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff	10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms	10 percent owner	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Aisling Capital Partners Iv Llc	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106